DAILIES TOTAL1 Multifocal Contact Lenses for Presbyopia
(INFUSETODT1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine the comfort and vision of DAILIES TOTAL1 Multifocal contact lenses in a population of satisfied INFUSE One-Day Multifocal contact lens wearers
Are You a Good Fit for This Trial?
This trial is for adults who are currently happy with their INFUSE One-Day Multifocal contact lenses and have presbyopia (age-related trouble seeing up close).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are refit from INFUSE One-Day Multifocal to DAILIES TOTAL1 Multifocal contact lenses and followed for comfort and vision assessment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Trial Overview
The study tests how comfortable and effective DAILIES TOTAL1 Multifocal contact lenses are when worn by people already using another brand of multifocal daily contacts. Participants will switch to the new lens to compare comfort and vision.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants currently wearing INFUSE One-Day Multifocal (kalifilcon A) are refit into DAILIES TOTAL1 Multifocal (delefilcon A) daily disposable contact lenses and followed for approximately 3 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gordon Schanzlin New Vision
Lead Sponsor
Alcon Research
Industry Sponsor
Raquel C. Bono
Alcon Research
Chief Medical Officer since 2022
MD from Harvard Medical School
David Endicott
Alcon Research
Chief Executive Officer since 2018
MBA from University of Southern California
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.